The blockbuster transactions continue in the cannabis space, with Aphria (TSX:APH; OTC:APHQF)’s acquisition of Nuuvera (TSXV:NUU) being the latest, announced on Monday (January 29) for $826 million.
This buyout comes on the heels of fellow LP Aurora Cannabis (TSX:ACB; OTCQB:ACBFF) completing its acquisition of CanniMed Therapeutics (TSX:CMED) for nearly $1.1 billion last week.
According to a joint statement, Aphria will now take command of Nuuvera’s international options, expanding the depth of its international reach. This move comes in the wake of experts predicting the potential for more mergers and acquisition taking place throughout 2018.
“The transaction provides our shareholders with significant value for their investment in Nuuvera and the opportunity to participate in the significant upside of the combined company,” Lorne Abony, CEO of Nuuvera said.

Terms of the buyout from Aphriawhat are inversion deals

Aphria will buy all of Nuuvera’s issued and outstanding common shares, at a price of $8.50 per share. “Nuuvera shareholders will receive $1.00 in cash plus 0.3546 of an Aphria share for each Nuuvera share held which,” the release said.
According to the companies, the buyout will reduce costs from their already established partnership through offtake agreements. On January 11, Aphria and Nuuvera revealed they were in discussions for one of these deals for 60,000 kilograms of cannabis production.
Nuuvera is a smaller producer with intentions on the global cannabis market, counting opportunities in Germany, Israel, and Italy. Its play for the Italian market expanded this month when the company acquired one of the seven licenses to import medical cannabis into the country.


Canadian cannabis market at an international level

With the expected increase in demand for marijuana, Canadian cannabis producers with established business paths are seeking new means of production to meet the interest of in cannabis products, with the recreational legalization of the drug is slated for summer 2018.
On an international level, The international options are opening up for Canadian LPs as well. As companies continue their development plans, markets that are just starting to take off are looking to Canadian producers for guidance and leadership.
Despite the growing excitement for the Canadian cannabis market, both recreational and medical, some companies have started looking beyond that for their overall growth.
According to Bloomberg, Vic Neufeld said in a call with investors, the hope is to have 20 countries under license in a year’s time.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Investor Takeaway

Following the announcement, Nuuvera’s share price rose over 10 percent. On Monday the company closed with a value of $7.73 per share, representing a 10.43 percent increase. This year Nuuvera’s share price has been struggling; at market close on Friday (January 26), its share price had decreased 54.18 percent.
Tim Seymour, a managing partner with Triogem Asset Management tweeted on Monday this deal could open the doors to Aphria having the largest global “footprint.”


During an analyst panel at the Cannabis Lift Expo in Vancouver, the group of experts discussed how merger and acquisition activity in this market could ramp up in 2018. It will be key for investors to keep track of what companies continue their acquisitions.
Don’t forget to follow us @INN_Cannabis for real-time news updates!
Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

Khiron Life Sciences Corp. (“ Khiron ” or, the “ Company ”) (TSXV: KHRN), (OTCQB: KHRNF), (Frankfurt: A2JMZC), announced today that it has re-filed its unaudited condensed interim consolidated financial statements, together with the notes thereto, for the three and six months ended June 30, 2020 and 2019 (the “ Interim Financial Statements ”) to correct, among other things, certain 2019 comparative period information and to update certain presentation arising from the Company’s early adoption of IFRS 3 in late 2019, which changes were identified in connection with the Company’s review engagement with its auditor. The Company does not consider these adjustments either individually nor in the aggregate, to be material.

The re-filed Interim Financial Statements reflect changes to the Condensed Interim Consolidated Statements of Loss and Comprehensive Loss comparative period to remove transaction fees from the income statement and capitalize them to the applicable acquisition in accordance with the Company’s early adoption of the amended IFRS 3 as set out in Note 2, and to reclassify $1 million from general and administrative expenses to transaction fees for presentation purposes to conform with the Company’s presentation used in its audited consolidated financial statements for the years ended December 31, 2019 and 2018 (the “ Audited Annual Financial Statements ”). The re-filed interim Financial Statements also reflect changes to the Condensed Interim Consolidated Statement of Changes in Shareholders’ Equity to correct the 2019 comparative period balances as they incorrectly reflect Q1 2019 period balances, update certain presentation to conform with the Company’s presentation used in its Audited Annual Financial Statements; and reduce the valuation conclusion of the Company’s acquisition of NettaGrowth International Inc. to conform with the Audited Annual Financial Statements. The re-filed Interim Financial Statements also bring forward the subsequent event note disclosure.

Keep reading... Show less

Part of “Rooted in Good” CSR Platform, “Feed the Block” Gives Back Through Strategic Social Partnerships with Local Organizations Focused on Food Insecurity

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading U.S. provider of consumer products in cannabis, today announced a multi-state fundraising initiative in which proceeds will benefit 24 locally run food banks, homeless shelters and nonprofits working to proactively address the needs of those facing food insecurity in communities across America. This effort is a part of the Strategic Social Partnerships pillar within Curaleaf’s “Rooted in Good” Corporate Social Responsibility platform.

Keep reading... Show less

On September 8, 2020, Aurora Cannabis Inc. (NYSE:ACB) stunned the market when it announced that it expected to record up to $1.8 billion in goodwill impairment charges in the fourth quarter of 2020. On the same day, Aurora also announced a charge of approximately $140 million in the carrying value of certain inventory, and that it was appointing a new chief executive officer. On this news, Aurora’s stock fell approximately 11.6% in just one day. Since May 2020, Aurora’s stock is down approximately $10.00 per share

A lawsuit alleging violations of federal securities laws has been filed against Aurora and certain of its officers and directors. The suit alleges, among other things, that Aurora misled investors as to the value of prior acquisitions, that the Company had experienced degradation in certain assets, and that as a result, it was foreseeable that Aurora would record significant goodwill and asset impairment charges. According to the lawsuit, this news was so shocking because Aurora had previously lauded a “business transformation plan” that would purportedly “better align the business financially with the current realities of the cannabis market.”

Keep reading... Show less

  • Exclusive patent licensed from University of Idaho.
  • Mustard-derived fumigation of stored food – targeting vegetables and potatoes.
  • Leading agrochemical for sprout suppression – chlorpropham – banned by European Union on Oct. 8, 2020.
  • Appointment of Scientific Advisor Dr. Matthew J. Morra, professor emeritus of soil biochemistry at University of Idaho.

 MustGrow Biologics Corp. (CSE: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company”, “MustGrow”) is pleased to announce the exclusive patent licensing from the University of Idaho pertaining to a natural biopesticide mustard-based treatment of stored produce and other foods, particularly sprout suppression of potatoes.

Keep reading... Show less

Study represents the first research completed on the long-term toxicity and lifespan effects of cannabidiol in the preclinical model C. elegans

Canopy Growth Corporation (“Canopy Growth” or the “Company”) (TSX: WEED) (NASDAQ: CGC) and its medical division, Spectrum Therapeutics, have completed and published a new study on the long-term effects of cannabidiol (CBD), specifically focusing on toxicity and lifespan effects of CBD in the preclinical model C. elegans.

Keep reading... Show less